Low neuropsychologic performance among adult cancer survivors treated with chemotherapy

被引：52

作者：

Robert J. Ferguson

Tim A. Ahles

机构：

[1] Behavioral Medicine Section, Department of Psychiatry, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756, One Medical Center Drive

来源：

Current Neurology and Neuroscience Reports | 2003年 / 3卷 / 3期

关键词：

Tamoxifen; Cancer Survivor; Cognitive Decline; Systemic Chemotherapy; Cognitive Rehabilitation;

D O I：

10.1007/s11910-003-0081-2

中图分类号：

学科分类号：

摘要：

Decline in neuropsychologic test performance following adjuvant chemotherapy for various types of cancer has gained much research attention over the past decade. From available data, about one fourth to one third of individuals undergoing systemic chemotherapy exhibit measurable decrements in performance of standard tests of cognitive function. Many cancer survivors report that cognitive problems interfere with function and compromise quality of life. However, these declines appear subtle and there are little available longitudinal data examining pre- to post-treatment cognitive change. Further, there is little available evidence identifying the causes of cognitive decline. This paper reviews current literature on low neuropsychologic performance following systemic chemotherapy and hypotheses on the causes of cognitive symptoms following chemotherapy. Future research directions, with emphasis on longitudinal research design as well as treatment implications, are discussed. Copyright © 2003 by Current Science Inc.

引用

页码：215 / 222

页数：7

共 42 条

[1]

Olin J.J., Cognitive function after systemic therapy for breast cancer, Oncology, 15, pp. 613-624, (2001)

[2]

Ahles T.A., Saykin A., Cognitive effects of standard-dose chemotherapy in patients with cancer, Cancer Invest., 19, pp. 812-820, (2001)

[3]

Meyers C.A., Neurocognitive dysfunction in cancer patients, Oncology, 14, pp. 75-79, (2000)

[4]

McCarthy N.J., Swain S.M., Update on adjuvant chemotherapy for early breast cancer, Oncology, 14, pp. 1267-1280, (2000)

[5]

Cancer Care Issues in the United States: Quality of Care, Quality of Life, (1999)

[6]

Ferrell B.R., Hassey R., Dow K., Quality of life among long-term cancer survivors, Oncology, 11, pp. 565-576, (1997)

[7]

Ahles T.A., Saykin A.J., Furstenberg C.T., Et al., Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma, J. Clin. Oncol., 20, pp. 485-493, (2002)

[8]

van Dam F.S., Schagen M., Muller S.B., Et al., Impairment of cognitive function in women receiving adjuvant treatment for high risk breast cancer: High dose versus standard dose chemotherapy, J. Natl. Cancer Inst., 90, pp. 210-218, (1998)

[9]

Schagen S.B., Hamberger H.L., Muller M.J., Et al., Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function, J. Neuro-Oncol., 51, pp. 159-165, (2001)

[10]

Walch S.E., Ahles T.A., Saykin A.J., Neuropsychological impact of cancer and cancer treatments in adults, Psycho-Oncology, (1998)

← 1 2 3 4 5 →